Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hologic Inc Issues Q3 2013 Guidance Below Analysts' Estimates; Lowers FY 2013 Guidance


Monday, 6 May 2013 04:01pm EDT 

Hologic Inc announced that for the third quarter of 2013, it expects revenues of $625 million to $630 million and non--GAAP adjusted EPS of $0.36 to $0.37. For fiscal 2013, the Company is updating its expectation for non--GAAP adjusted revenues of $2.53 billion to $2.55 billion (from its previous expectation of $2.61 billion to $2.64 billion). The updated fiscal 2013 revenue guidance represents an increase of 26% to 27% over fiscal 2012 non--GAAP adjusted revenues of $2.01 billion. This increase is expected to be driven primarily by the Gen--Probe acquisition and, to a lesser extent, revenue increases in the Breast Health, GYN Surgical and legacy Diagnostics segments, partially offset by a reduction in Adiana system revenues ($11.1 million in year ended September 29, 2012). The Company now expects non--GAAP adjusted EPS of $1.54 to $1.56. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $655 million and EPS of $0.41 for the third quarter of 2013; revenues of $2.63 billion and EPS of $1.58 for fiscal 2013. 

Company Quote

26.97
0.08 +0.30%
12:30pm EST